AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6113858
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg terfenadine suspension
Trial: 6113858
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of 14C terfenadine
Trial: 6113858
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of 14C
Trial: 28849773
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (20 µg) hepatitis B vaccine
Trial: 28849773
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (10 µg) hepatitis B vaccine
Trial: 25670366
Drug: Anacetrapib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib (150 and 300 mg/d)
Trial: 25670366
Drug: Anacetrapib +
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib + Atorvastatin
Trial: 25670366
Drug: Atorvastatin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin alone vs placebo
Trial: 22711385
Drug: Multivitamin, mineral
RxNorm normalized name: multivitamin, minerals no.51/folic acid/vit K1/ubidecarenone 100 mcg-350 mcg-5 mg ORAL TABLET,CHEWABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin, mineral and herbal supplement (Swisse Men's Ultivite®)
Trial: 17376293
Drug: nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nateglinide (120 mg)
Trial: 15736118
Drug: acarbose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acarbose (50 mg)
Trial: 15199325
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of non-nucleoside reverse transcriptase inhibitors (NNRTI) from current therapy
Trial: 15199325
Drug: Non-nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleoside reverse transcriptase inhibitors (NNRTI)
Trial: 1190686
Drug: Methylprednisolone, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone, 10 mg/kg intravenously at 8-hour intervals for three doses
Trial: 22334056
Drug: Aerobic training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic training (50 minutes, four times weekly for 24 weeks)
Trial: 22334056
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (health lectures twice a month)
Trial: 23565931
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment for hypertension
Trial: 18549492
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care interventions (three step treatment approach: step 1 - behavioural change counselling, step 2 - three sessions of motivational enhancement therapy, step 3 - referral to specialist services)
Trial: 12610040
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine prebedtime plus lispro preprandially (LIS/GLAR)
Trial: 12610040
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin prebedtime plus regular human insulin preprandially (R/NPH)
Trial: 31212997
Drug: Neo-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemotherapy
Trial: 7577201
Drug: Less extensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less extensive treatment
Trial: 31932201
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplement 2000 IU per day for 2 months
Trial: 26988095
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention for GPs on inhalation techniques (one session with a monitor)
Trial: 20205074
Drug: Asenapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine (5 or 10 mg BID)
Trial: 22454251
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 or 20 mg QD)
Trial: 18021264
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin 1 g, 1 h pre-operatively and 2 g for 2 days post-operatively (Antibiotics group)
Trial: 18021264
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (Non-antibiotics group)
Trial: 9197875
Drug: Continuous 17
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 17 beta‐oestradiol orally (2 mg daily)
Trial: 9197875
Drug: Continuous 17
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 17 beta‐oestradiol transdermally (50 micrograms daily)
Trial: 1527230
Drug: Methylphenidate or
RxNorm normalized name: methylphenidate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate or dextroamphetamine in individualized doses
Trial: 23611825
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (100,000 IU orally every 3 months for 4 doses)
Trial: 19926166
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antibiotics unless clinically indicated)
Trial: 1582188
Drug: Oxprenolol (non-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (non-selective beta-blocker with moderate intrinsic sympathomimetic activity), given by the Oros delivery system
Trial: 1582188
Drug: Atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta 1-selective blocker without ISA)
Trial: 23536963
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of black pepper essential oil for 2 minutes
Trial: 23536963
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of angelica essential oil for 2 minutes
Trial: 15161771
Drug: Pioglitazone (P+)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (P+) 45 mg for 21 days
Trial: 12101864
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg or 600 mg) and Misoprostol (400 micrograms)
Trial: 12101864
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg or 600 mg) and Misoprostol (600 micrograms)
Trial: 12101864
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg and Misoprostol (400 micrograms)
Trial: 9867054
Drug: Clinical benefits
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical benefits of steroids
Trial: 2536867
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: two courses of three sequential drug combinations (1) cyclophosphamide, lomustine, and methotrexate; (2) cyclophosphamide, doxorubicin, and vincristine; (3) ifosfamid and etoposide
Trial: 9388412
Drug: Brassiodol (iodised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brassiodol (iodised rapeseed oil) at a dose of 2 mL
Trial: 3279725
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg b.i.d. with moderate dietary salt reduction
Trial: 3279725
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg b.i.d. with hydrochlorothiazide 25 mg daily
Trial: 17581217
Drug: Benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10 mg/day, p.o.)
Trial: 15699266
Drug: avasimibe 750
RxNorm normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: avasimibe 750 mg QDS for 8 weeks
Trial: 10544534
Drug: nasally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasally administered continuous positive airway pressure (CPAP) therapy
Trial: 10544534
Drug: recent technological
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: recent technological developments in CPAP therapy
Trial: 10544534
Drug: semiattended and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semiattended and unattended settings for CPAP therapy
Trial: 23123345
Drug: Doxycycline (200mg/day)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline (200mg/day) for 23 days followed by doxycycline (200mg/day) in combination with albendazole (ABZ) (400mg/day) for 7 days
Trial: 23123345
Drug: Doxycycline and
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline and ABZ in combination
Trial: 19514296
Drug: Combined therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapeutic modalities with magnetopuncture therapy
Trial: 19514296
Drug: Combined therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapeutic modalities without magnetopuncture therapy
Trial: 16691061
Drug: 6% cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% cellulose sulfate (CS) gel
Trial: 11350571
Drug: High-dose nimodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nimodipine (2-mg h(-1))
Trial: 11350571
Drug: Low-dose nimodipine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nimodipine (1-mg h(-1))
Trial: 8498421
Drug: 587 mg
RxNorm normalized name: choline salicylate 587 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 587 mg calcium per day
Trial: 8498421
Drug: 1336 mg
RxNorm normalized name: Mg
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1336 mg calcium per day
Trial: 8498421
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg manganese per day
Trial: 8498421
Drug: 5.6 mg
RxNorm normalized name: menthol 5.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.6 mg manganese per day
Trial: 2958819
Drug: Methylprednisolone 40
RxNorm normalized name: methylprednisolone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 40 mg intramuscularly and intravenously
Trial: 31885292
Drug: Positive mycoplasma
RxNorm normalized name: Mycoplasma pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive mycoplasma pneumoniae (MP) antibody IgM
Trial: 31913413
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel alone or with carboplatin and/or veliparib for 12 weeks followed by 4 cycles of doxorubicin hydrochloride and cyclophosphamide
Trial: 31913413
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel alone or with carboplatin and/or veliparib
Trial: 25372086
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (25 mg etanercept plus methotrexate)
Trial: 16549707
Drug: 3-injection site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-injection site pattern (3 injections of 10 U of botulinum toxin A)
Trial: 16549707
Drug: 5-injection site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-injection site pattern (5 injections of 10 U of botulinum toxin A)
Trial: 25517733
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 injections)
Trial: 16549707
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 injections)
Trial: 11156724
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enoxaparin and abciximab
Trial: 9052285
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg of dexamethasone
Trial: 30990088
Drug: Dyadic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyadic treatment (STAND)
Trial: 30944269
Drug: Metformin 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1,500 mg/d
Trial: 19796088
Drug: Li-PDT-PC (5-ALA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Li-PDT-PC (5-ALA 0.5% liposomal spray and intense pulsed light in combination with topical peeling agents)
Trial: 19796088
Drug: Li-PDT-PC-AT (Li-PDT-PC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Li-PDT-PC-AT (Li-PDT-PC with additional topical or systemic antibiotics)
Trial: 18428095
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment plus three-weekly CM sessions for 5 weeks
Trial: 16804925
Drug: Prior chemotherapy
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior chemotherapy
Trial: 12563672
Drug: Anakinra (0.04,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (0.04, 0.1, 0.4, 1, or 2 mg/kg once daily for 24 weeks)
Trial: 12563672
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in addition to MTX 15 to 25 mg/wk)
Trial: 1862257
Drug: Erdosteine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine (300 mg t.i.d.) for 8 days
Trial: 31693746
Drug: Mean arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean arterial pressure treatment only (Group 1)
Trial: 24059983
Drug: Intensive integrative
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive integrative language therapy (at least 2 hours/day and at least 10 hours/week for at least three weeks)
Trial: 19522426
Drug: Clomifene citrate
RxNorm normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomifene citrate plus metformin 850 mg two times a day
Trial: 17308899
Drug: Olpadronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpadronate (10 mg/m2/day)
Trial: 14973308
Drug: PNU-96391 1
RxNorm normalized name: Alternaria alternata allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-96391 1 mg
Trial: 14973308
Drug: PNU-96391 3
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-96391 3 mg
Trial: 14973308
Drug: PNU-96391 10
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-96391 10 mg
Trial: 14973308
Drug: PNU-96391 30
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-96391 30 mg
Trial: 14973308
Drug: PNU-96391 100
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-96391 100 mg
Trial: 14973308
Drug: PNU-96391 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-96391 150 mg
Trial: 14973308
Drug: PNU-96391 200
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-96391 200 mg
Trial: 9054234
Drug: 21-mg/day nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21-mg/day nicotine patches
Trial: 9054234
Drug: 14-mg/day nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-mg/day nicotine patches
Trial: 9054234
Drug: 7-mg/day nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-mg/day nicotine patches
Trial: 7946592
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + MPA therapy (CAF: CPA 100 mg orally days 1-14, ADR 30 mg/m2 i.v. days 1 and 8, 5-FU 500 mg/m2 i.v. days 1 and 8; MPA 1200 mg daily)
Trial: 7946592
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + MPA therapy
Trial: 7946592
Drug: CAF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF therapy (control)
Trial: 29439648
Drug: Tiotropium/olodaterol 5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/olodaterol 5/5 µg
Trial: 29439648
Drug: Tiotropium/olodaterol 2.5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/olodaterol 2.5/5 µg
Trial: 21633921
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of circulating progenitor cells (CPC) or bone marrow-derived progenitor cells (BMC)
Trial: 18350925
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and radiotherapy
Trial: 18350925
Drug: Palliative chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative chemotherapy, radiotherapy, and surgery
Trial: 1516461
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg cefetamet syrup, given orally twice daily for 7 days
Trial: 1516461
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg cefaclor, given orally twice daily for 7 days
Trial: 30306325
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl tablet
Trial: 26912469
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention by pharmacists to inform patients about adverse effects of medications
Trial: 26912469
Drug: Patients unaware
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients unaware of adverse effects of medications
Trial: 24368588
Drug: Chlorhexidine (CHX)
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX) mouth rinsing twice daily and no brushing
Trial: 20498245
Drug: MMF 3-g
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 3-g arm (1.5 g twice daily on days 1 to 5, then 1.0 g twice daily)
Trial: 20498245
Drug: MMF 2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 2-g arm (1.0 g twice daily)
Trial: 20498245
Drug: MMF 3-g
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 3-g arm
Trial: 20498245
Drug: MPA AUC
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA AUC levels <30 mg.h/L
Trial: 20498245
Drug: MMF 3-g
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 3-g arm and MMF 2-g arm
Trial: 17645881
Drug: 24 mg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg/min vitamin C
Trial: 12043854
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension 0.25 mg twice daily
Trial: 9819296
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension 0.50 mg twice daily
Trial: 9819296
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension 1.0 mg twice daily
Trial: 9819296
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (all doses)
Trial: 8569263
Drug: Western drugs
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western drugs (WM group)
Trial: 21918063
Drug: Fortified choco-malt
RxNorm normalized name: malt extract
DrugBank: Barley malt syrup (DB14601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified choco-malt beverage powder (40 g daily for 120 days)
Trial: 21918063
Drug: Matched energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched energy equivalent unfortified placebo (40 g daily for 120 days)
Trial: 11324210
Drug: Narrow-diameter self-tapping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-diameter self-tapping implants (3.25-mm)
Trial: 11324210
Drug: Standard-diameter self-tapping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-diameter self-tapping implants (3.75-mm)
Trial: 3076661
Drug: Nisoldipine 5
RxNorm normalized name: nisoldipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 5 mg/day
Trial: 3076661
Drug: Nisoldipine (2.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (2.5-20 mg/day)
Trial: 3076661
Drug: Nisoldipine (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (twice daily)